Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.06 USD

41.06
1,817,913

+0.74 (1.84%)

Updated Aug 13, 2024 01:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

LabCorp, Unilabs Tie Up to Expand in Companion Diagnostics

LabCorp (LH) continues to strengthen hold in the diagnostics space through inorganic means.

    Novartis Announces Positive Data on Kisqali and Tasigna

    Novartis (NVS) announces positive data on breast cancer drug Kisqali and oncology drug Tasigna at the ASCO.

      Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO

      Merck (MRK) presents data from several cancer studies of its PD-L1 inhibitor, Keytruda at ASCO including two key lung cancer trials.

        LabCorp Extends Aetna Agreement, Expands Diagnostics Business

        The expanded agreement enables LabCorp (LH) to serve as a preferred national laboratory to almost all of Aetna's members starting Jan 1, 2019.

          Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

          Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

            AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why

            AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline

              The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive

              The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive

                Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

                Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

                  AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

                  AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

                    Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

                    Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.

                      Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook

                      Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.

                        HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?

                        Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.

                          Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid

                          Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.

                            What's in the Cards for Merck (MRK) This Earnings Season?

                            Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.

                              Glaxo (GSK) Misses on both Earnings and Revenue in Q1

                              Glaxo's (GSK) Q1 earnings and revenue miss estimates. In the event of introduction of Advair generic in the U.S. market by mid-year, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

                                What's in the Cards for Glaxo (GSK) This Earnings Season?

                                Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

                                  Novartis (NVS) Beats Earnings and Revenue Estimates in Q1

                                  Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.

                                    Sanofi to Divest European Generic Unit, Streamline Business

                                    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

                                      Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why

                                      Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.

                                        Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?

                                        The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

                                          Glaxo to Sell Rare Disease Gene Therapies to Private Biotech

                                          Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.

                                            Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

                                            Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

                                              J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?

                                              The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

                                                Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III

                                                Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.

                                                  Tracey Ryniec headshot

                                                  What All Investors Should Know about Trade Deficits and Recessions

                                                  What's the trade deficit really about? And what are the key signals that may alert investors to an upcoming recession?